Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Rating of “Moderate Buy” by Analysts

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has earned an average recommendation of “Moderate Buy” from the seventeen analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $685.3077.

A number of analysts recently issued reports on MDGL shares. Barclays started coverage on Madrigal Pharmaceuticals in a report on Tuesday, January 27th. They set an “overweight” rating and a $964.00 price objective on the stock. Citigroup reaffirmed an “outperform” rating on shares of Madrigal Pharmaceuticals in a report on Tuesday, January 20th. Piper Sandler upped their price target on Madrigal Pharmaceuticals from $540.00 to $900.00 and gave the company an “overweight” rating in a research report on Friday, December 19th. TD Cowen reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Monday, January 12th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $571.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Wednesday, January 14th.

Madrigal Pharmaceuticals Trading Down 1.5%

Shares of MDGL stock opened at $432.83 on Friday. The stock has a market capitalization of $9.93 billion, a price-to-earnings ratio of -33.63 and a beta of -0.97. The company’s fifty day simple moving average is $492.64 and its two-hundred day simple moving average is $487.47. Madrigal Pharmaceuticals has a 1 year low of $265.00 and a 1 year high of $615.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.01 and a quick ratio of 3.77.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). The company had revenue of $321.08 million during the quarter, compared to the consensus estimate of $310.36 million. Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.Madrigal Pharmaceuticals’s revenue was up 210.8% on a year-over-year basis. During the same period in the previous year, the business earned ($2.71) earnings per share. As a group, analysts anticipate that Madrigal Pharmaceuticals will post -23.47 earnings per share for the current year.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Company granted inducement equity awards to 20 new non‑executive hires under Nasdaq Rule 5635(c)(4), which can help recruit talent and support execution of the pipeline programs. Madrigal Announces Grants of Inducement Awards
• Neutral Sentiment: All insider trades were formally reported via SEC Form 4 filings (standard disclosure), so the transactions are public and fully documented. Example SEC Form 4 Filing
• Negative Sentiment: CEO William John Sibold sold 1,663 shares (~$718k); his holdings fell ~1.02% after the sale. CEO Form 4
• Negative Sentiment: CFO Mardi Dier sold 1,982 shares (~$854k); this represented a ~13.7% reduction in her ownership. Large percentage cuts by the CFO can be read as a stronger negative signal. CFO Form 4
• Negative Sentiment: General Counsel Shannon T. Kelley sold 360 shares (~$155k), a ~2.88% position reduction. GC Form 4
• Negative Sentiment: Director Rebecca Taub sold 491 shares (~$212k); she still retains a large stake (~452k shares) but reduced ownership slightly. Director Form 4
• Negative Sentiment: Insider Carole Huntsman sold 419 shares (~$181k), a ~3.20% decrease in her holding. Insider Form 4

Insider Activity

In related news, CFO Mardi Dier sold 1,982 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $430.87, for a total transaction of $853,984.34. Following the completion of the transaction, the chief financial officer owned 12,490 shares in the company, valued at $5,381,566.30. This represents a 13.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul A. Friedman sold 24,800 shares of the stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $552.18, for a total transaction of $13,694,064.00. Following the completion of the transaction, the director directly owned 187,164 shares of the company’s stock, valued at approximately $103,348,217.52. The trade was a 11.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 99,062 shares of company stock valued at $52,317,727. Insiders own 21.50% of the company’s stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AlphaQuest LLC boosted its holdings in shares of Madrigal Pharmaceuticals by 412.5% during the 2nd quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 66 shares in the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of Madrigal Pharmaceuticals in the 4th quarter worth about $29,000. Mather Group LLC. purchased a new position in Madrigal Pharmaceuticals during the 3rd quarter valued at about $33,000. Global Retirement Partners LLC lifted its position in Madrigal Pharmaceuticals by 221.7% during the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 51 shares during the period. Finally, First Horizon Corp bought a new stake in Madrigal Pharmaceuticals during the third quarter worth about $34,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.